For example, a study demonstrated that inhibiting Extracellular signal-regulated kinase 2 (ERK2) kinases using CRISPR/Cas technology enhanced the responsiveness of HCC cells to sorafenib, a multi-kinase inhibitor widely prescribed for HCC treatment [136]. The gene discussed is MAPK1; the disease is hepatocellular carcinoma.